Proflavine

PreclinicalSmall molecule

MM.D. Anderson Cancer Center

Proflavine is one of 53 small molecule programs targeting Adenocarcinoma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AdenocarcinomaActive, not recruiting

AdenocarcinomaPreclinical

Active, not recruiting

Competition

Competitive Landscape

90 competitors in Adenocarcinoma

#DrugCompanyPhaseTrials

Eloxatin

Teva

Phase 3

43 2

Gemzar

Johnson & Johnson

Phase 3

16 3

Taxol

Teva

Phase 3

14 4

Keytruda

Merck & Co.

Phase 3

14 5

Taxotere

AAvyxa

Phase 3

19 6

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

17 7

Beyfortus

BeiGene

Phase 3

4 8

Wellcovorin

GGlaxo Dba Glaxosmithkline

Phase 3

11 9

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

5 10

PD-1 Inhibitor

Johnson & Johnson

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

PreclinicalRecruiting

Neoplasm

NCT01269190

Clinical

Trials by Indication[1]

Endoscopy2 trials

Use of High-Resolution Microendoscopy (HRME) in Patients With Cervical Dysplasia

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT02420665·50 enrolled

High-Resolution Microendoscopy to Guide Hysteroscopic Tumor Resection

Withdrawn·MM.D. Anderson Cancer Center·Phase 2·NCT02095847

Cervical Cancer2 trials

Cervical Cancer Screening Study in Brazil

Completed·MM.D. Anderson Cancer Center·N/A·NCT02335372·300 enrolled

Low-Cost Imaging for Cervical Cancer Prevention in the Texas Lower Rio Grande Valley

Terminated·TThe University of Texas Medical Branch, Galveston·Phase 1·NCT02714439·157 enrolled

Adenocarcinoma1 trial

Use of High-Resolution Microendoscopy (HRME) in Patients With Adenocarcinoma In-Situ (AIS) of the Cervix

Completed·MM.D. Anderson Cancer Center·N/A·NCT02206048·9 enrolled

Esophageal Squamous Cell Cancer1 trial

Evaluation of a Miniaturized Microscope Device for the Detection of Esophageal Squamous Cell Cancer

Completed·—·Phase 1·NCT01384708·70 enrolled

Imaging1 trial

Endoscopic Multispectral Imaging for the Early Detection of Barrett's Neoplasia

Completed·—·Phase 1·NCT01384864·30 enrolled

2 more indications

Intestinal Cancer1 trial

Acceptability and Performance of a Mobile Optical Biopsy Technology for Gastrointestinal Cancer Screening

Completed·—·Phase 2·NCT05396781·41 enrolled

Neoplasm1 trial

Wide-Field and High Resolution In Vivo Imaging of Oral Neoplasia Using Topical Fluorescent Dyes: A Feasibility Study

Recruiting·MM.D. Anderson Cancer Center·Preclinical·NCT01269190·275 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Proflavine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Proflavine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Proflavine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — M.D. Anderson Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: MM.D. Anderson Cancer Center

Proflavine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Endoscopy2 trials

Cervical Cancer2 trials

Adenocarcinoma1 trial

Esophageal Squamous Cell Cancer1 trial

Imaging1 trial

Intestinal Cancer1 trial

Neoplasm1 trial

References

Drug Info

Quick Facts

Related News